Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

FARICIMAB-SVOA: 1,908 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
1,908
Total FAERS Reports
175 (9.2%)
Deaths Reported
169
Hospitalizations
1,908
As Primary/Secondary Suspect
7
Life-Threatening
58
Disabilities
Prescription
Status

FDA Application: 761235 ·

First Report: 20090101 · Latest Report: 20250918

What Are the Most Common FARICIMAB-SVOA Side Effects?

#1 Most Reported
Off label use
453 reports (23.7%)
#2 Most Reported
No adverse event
259 reports (13.6%)
#3 Most Reported
Death
158 reports (8.3%)

All FARICIMAB-SVOA Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Off label use 453 23.7% 27 28
No adverse event 259 13.6% 0 0
Death 158 8.3% 153 1
Visual impairment 146 7.7% 1 15
Eye inflammation 136 7.1% 0 5
Blindness 127 6.7% 0 8
Endophthalmitis 125 6.6% 1 9
Uveitis 102 5.4% 0 12
Vitritis 90 4.7% 0 13
Drug ineffective 82 4.3% 0 3
Vision blurred 80 4.2% 0 10
Iridocyclitis 76 4.0% 0 9
Vitreous floaters 65 3.4% 0 3
Eye pain 61 3.2% 0 10
Retinal haemorrhage 51 2.7% 0 3
Intraocular pressure increased 45 2.4% 0 5
Iritis 45 2.4% 0 2
Visual acuity reduced 44 2.3% 0 4
Inflammation 42 2.2% 0 1
Eye disorder 40 2.1% 0 5

Who Reports FARICIMAB-SVOA Side Effects? Age & Gender Data

Gender: 57.0% female, 43.0% male. Average age: 73.5 years. Most reports from: US. View detailed demographics →

Is FARICIMAB-SVOA Getting Safer? Reports by Year

YearReportsDeathsHosp.
2009 1 0 0
2015 1 0 0
2017 3 0 1
2020 2 0 0
2021 1 0 0
2022 130 5 11
2023 156 18 21
2024 260 42 48
2025 166 23 30

View full timeline →

What Is FARICIMAB-SVOA Used For?

IndicationReports
Neovascular age-related macular degeneration 725
Product used for unknown indication 473
Diabetic retinal oedema 256
Age-related macular degeneration 117
Retinal vein occlusion 104
Macular oedema 77
Diabetic retinopathy 71
Macular degeneration 67
Choroidal neovascularisation 65
Dry age-related macular degeneration 19

FARICIMAB-SVOA vs Alternatives: Which Is Safer?

FARICIMAB-SVOA vs FARICIMAB\FARICIMAB-SVOA FARICIMAB-SVOA vs FASLODEX FARICIMAB-SVOA vs FAVIPIRAVIR FARICIMAB-SVOA vs FEBUXOSTAT FARICIMAB-SVOA vs FEDRATINIB FARICIMAB-SVOA vs FELBAMATE FARICIMAB-SVOA vs FELIS CATUS HAIR FARICIMAB-SVOA vs FELODIPINE FARICIMAB-SVOA vs FENFLURAMINE FARICIMAB-SVOA vs FENOFIBRATE

Official FDA Label for FARICIMAB-SVOA

Official prescribing information from the FDA-approved drug label.